<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Platelet Orai1 channels mediate store-operated Ca(2+) entry (SOCE), which is required for procoagulant activity and arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="1" pm="."><plain>Pharmacological blockage of these channels may provide a novel way of antithrombotic therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the thromboprotective effect of SOCE blockers directed against platelet Orai1 is determined </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Candidate inhibitors were screened for their effects on SOCE in washed human platelets </plain></SENT>
<SENT sid="4" pm="."><plain>Tested <z:chebi fb="68" ids="48706">antagonists</z:chebi> included the known compounds, SKF96365, <z:chebi fb="0" ids="22502">2-aminoethyl</z:chebi> diphenylborate, and MRS1845 and the novel compounds, Synta66 and GSK-7975A </plain></SENT>
<SENT sid="5" pm="."><plain>The potency of SOCE inhibition was in the order of Synta66&gt;<z:chebi fb="0" ids="22502">2-aminoethyl</z:chebi> diphenylborate&gt;GSK-7975A&gt;SKF96365&gt;MRS1845 </plain></SENT>
<SENT sid="6" pm="."><plain>The specificity of the first 3 compounds was verified with platelets from Orai1-deficient mice </plain></SENT>
<SENT sid="7" pm="."><plain>Inhibitory activity on procoagulant activity and high-shear <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was assessed in plasma and whole blood </plain></SENT>
<SENT sid="8" pm="."><plain>In the presence of plasma, <z:hpo ids='HP_0000001'>all</z:hpo> 3 compounds suppressed platelet responses and restrained <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation under flow </plain></SENT>
<SENT sid="9" pm="."><plain>Using a murine <z:hpo ids='HP_0001297'>stroke</z:hpo> model, arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was provoked in vivo by transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Postoperative administration of <z:chebi fb="0" ids="22502">2-aminoethyl</z:chebi> diphenylborate markedly diminished brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Plasma-soluble SOCE blockers such as <z:chebi fb="0" ids="22502">2-aminoethyl</z:chebi> diphenylborate suppress platelet-dependent coagulation and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="12" pm="."><plain>The platelet Orai1 channel is a novel target for preventing thrombotic events causing <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
</text></document>